Riccardo Pertile

Dr. Riccardo Pertile

Azienda Proviciale per i Servizi Sanitari di Trento, Italy, Trento, Trentino-Alto Adige, Italy
orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2012 in Psychiatry Research
Verified
Journal Article
Closed access
ARAlberto Rossi
Alberto Rossi
GCGaia Cetrano
Gaia Cetrano
RPRiccardo Pertile
Riccardo Pertile
LRLaura Rabbi
Laura Rabbi
VDValeria Donisi
Valeria Donisi
FAFrancesco Amaddeo
Francesco Amaddeo

2 March 2016 in Birth Defects Research Part A: Clinical and Molecular Teratology
Verified
Journal Article
Closed access
PDF file
Matteo CassinaMatteo Cassina
Matteo Cassina
MRMichele Ruol
Michele Ruol
RPRiccardo Pertile
Riccardo Pertile
Paola MidrioPaola Midrio
Paola Midrio
SPSilvano Piffer
Silvano Piffer
MCMaurizio Clementi
Maurizio Clementi

26 June 2010 in Social Psychiatry and Psychiatric Epidemiology
Verified
Journal Article
Closed access
PDF file
GZGrazia Zulian
Grazia Zulian
VDValeria Donisi
Valeria Donisi
GSGiacomo Secco
Giacomo Secco
RPRiccardo Pertile
Riccardo Pertile
MTMichele Tansella
Michele Tansella
FAFrancesco Amaddeo
Francesco Amaddeo

3 June 2019 in Acta Oncologica
Verified
Journal Article
Closed access
FDFrancesco Dionisi
Francesco Dionisi
SCS. Croci
S. Croci
IGI. Giacomelli
I. Giacomelli
MCM. Cianchetti
M. Cianchetti
ACA. Caldara
A. Caldara
MAM. Amichetti
M. Amichetti
Background and purpose: Recurrent nasopharyngeal carcinoma (NPC) has limited curative treatment options. Reirradiation is the only potential definitive treatment in advanced stages at a cost of substantial severe and often life-threatening toxicity. Proton therapy (PT) reduces irradiated volume compared with X-ray radiotherapy and could be advantageous in terms of safety and efficacy in a population of heavily pretreated patients. We report the retrospective results of PT reirradiation in recurrent NPC patients treated at our Institution Methods: All recurrent NPC patients treated since the beginning of clinical activity entered the present analysis. Clinical target volume consisted of Gross Tumor volume plus a patient-specific margin depending on disease behavior, tumor location, proximity of organs at risk, previous radiation dose. No elective nodal irradiation was performed. Active scanning technique with the use of Single Field Optimization (SFO) or Multifield Optimization (MFO) was adopted. Cumulative X-ray -PT doses were calculated for all patients using a dose accumulation tool since 2016. Treatment toxicity was retrospectively collected. Results: Between February 2015, and October 2018, 17 recurrent NPC patients were treated. Median follow-up (FUP) was 10 months (range 2–41). Median PT reirradiation dose was 60 Gy RBE (range 30.6–66). The majority of patients (53%) underwent concomitant chemotherapy. Acute toxicity was low with no ≥ G3 adverse events. Late events ≥ G3 occurred in 23.5% of patients. Most frequent late toxicity was hearing impairment (17,6%). G2 soft tissue necrosis occurred in two patients. Fatal bleeding of uncertain cause (either tumor recurrence or G5 carotid blowout) occurred in one patient. Kaplan–Meier 18 months Overall Survival (OS) and Local control (LC) rates were 54.4% and 66.6%, respectively. Conclusions: Our initial results with the use of modern PT for reirradiation of recurrent NPC patients are encouraging. Favorable LC and OS rates were obtained at the cost of acceptable severe late toxicity.

15 May 2010 in Social Psychiatry and Psychiatric Epidemiology
Verified
Journal Article
Closed access
PDF file
RPRiccardo Pertile
Riccardo Pertile
VDValeria Donisi
Valeria Donisi
LGLaura Grigoletti
Laura Grigoletti
AAAndrea Angelozzi
Andrea Angelozzi
GZGiuseppe Zamengo
Giuseppe Zamengo
FAFrancesco Amaddeo
Francesco Amaddeo

1 June 2007 in Neonatology
Verified
Journal Article
Closed access
MHMikko Hallman
Mikko Hallman
RMRiitta Marttila
Riitta Marttila
RPRiccardo Pertile
Riccardo Pertile
MOMarja Ojaniemi
Marja Ojaniemi
RHRitva Haataja
Ritva Haataja
Respiratory distress syndrome (RDS) and bronchopulmonary dysplasia (BPD) are common, serious lung diseases in preterm infants. Polymorphism of the genes involved in basic lung function and alveolar stability, lung differentiation and pulmonary host defense may influence the risk. Natural selection has refined the genes responsible for cardiopulmonary adaptation and resistance against pneumonia in term and near-term infants. Before the era of antibiotics, however, virtually all very preterm infants died of asphyxia, respiratory failure or infections. Today, the degree of prematurity plays a dominant role in susceptibility to serious lung disease. In addition, genetic polymorphism and constitution modulate the risk of RDS and BPD that have different, partly overlapping predisposition. According to twin studies, the genetic impact on the risk of RDS and BPD among preterm and very preterm infants is 35–65%. Individual disease genes generally have low penetrance. Large-scale genetic studies are required as part of neonatal and perinatal research in order to learn about the risk factors and to investigate pharmacogenetics. The aim in the future is to individualize therapies.